A Study Evaluating the Safety and Clinical Activity of HCV-796 in Treatment-Naive and Non-Responder Subjects

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2006
This is a phase 2, randomized, open-label study comparing the safety, antiviral activity, and pharmacokinetics of HCV-796 administered in combination with peginterferon alfa 2B (Peg-Intron) plus concomitant Rebetol vs. Peg-Intron plus Rebetol in Hepatitis C Virus (HCV) genotype 1-infected subjects who are either naive to treatment or who have previously failed treatment (non-responders).
Epistemonikos ID: d58ec7a7cafb1bb7cf6860f02fc0a8f5b4588b76
First added on: Mar 23, 2020